Table 4.

Correlation of COL10A1 mRNA expression and clinical prognosis in gastric cancer

	Overall survival	Post progression survival
	N HR p-Value	N HR p-Value
Sex Female Male	236 1.94(1.32–2.77) 0.00047 544 1.35(1.06–1.71) 0.013	149 1.48(0.95–2.29) 0.081 348 1.27(0.98–1.64) 0.074
Stage 1 2 3 4	69 0.11(0.02–0.49) 0.00046 140 0.65(0.34–1.23) 0.18 305 1.90(1.41–2.57) 1.7e-05 148 1.82(1.23–2.96) 0.0023	31 0.08(0.01–0.72) 0.0051 105 0.71(0.37–1.38) 0.31 142 2.6(1.63–4.14) 3.2e-05 104 1.45(0.89–2.38) 0.13
Stage T 1 2 3 4	14 - - 241 1.36(0.87–2.12) 0.18 204 1.76(1.25–2.49) 0.0011 38 0.56(0.24–1.35) 0.19	3 - - 196 1.25(0.79–1.99) 0.33 150 1.66(1.12–2.44) 0.0099 29 - -
Stage N 0 1 2 3 1 + 2 + 3	76 0.49(0.21–1.12) 0.085 225 1.97(1.30–3.00) 0.0012 121 2.78(1.60–4.85) 0.00016 76 1.79(1.03–3.09) 0.035 422 1.82(1.40–2.37) 6.6e-06	41 0.35(0.11–1.09) 0.059 169 1.61(1.02–2.53) 0.039 105 2.17(1.33–3.56) 0.0016 63 1.6(0.85–2.99) 0.14 337 1.6(1.2–2.13) 0.0011
Stage M 0 1	444 1.74(1.30–2.33) 0.00015 56 1.96(1.05–3.67) 0.33	342 1.51(1.12–2.04) 0.0068 36 2.35(1.04–5.33) 0.035
Lauren classification Intestinal Diffuse Mixed	320 2.20(1.59–3.04) 9.4e-07 241 1.66(1.16–2.36) 0.0049 32 – -	192 1.66(1.09–2.51) 0.0161 176 1.67(1.07–2.58) 0.021 16 – -
Differentiation Poorly differentiated Moderately differentiated Well differentiated	165 2.08(1.27–3.40) 0.0029 67 2.34(1.21–4.53) 0.0098 32 – -	49 1.36(0.72–2.58) 0.3428 24 – - 0 – -
HER2 status HER2 negative HER2 positive	532 1.22(0.96–1.56) 0.11 343 1.74(1.31–2.30) 8.6e-05	334 1.19(0.89–1.59) 0.24 164 1.53(1.04–2.26) 0.03